| Targeting different pathways using novel combination therapy in triple negative breast cancer MA Mir, H Qayoom, U Mehraj, S Nisar, B Bhat, NA Wani Current Cancer Drug Targets 20 (8), 586-602, 2020 | 74 | 2020 |
| An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer H Qayoom, NA Wani, B Alshehri, MA Mir Future Oncology 17 (31), 4185-4206, 2021 | 70 | 2021 |
| Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors S Sofi, U Mehraj, H Qayoom, S Aisha, A Almilaibary, M Alkhanani, MA Mir Medical Oncology 39 (9), 133, 2022 | 65 | 2022 |
| Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives U Mehraj, H Qayoom, MA Mir Breast Cancer 28 (3), 539-555, 2021 | 62 | 2021 |
| Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications S Sofi, U Mehraj, H Qayoom, S Aisha, SMB Asdaq, A Almilaibary, MA Mir Medical Oncology 39 (6), 106, 2022 | 60 | 2022 |
| Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD simulation study MMA Qayoom H, Mehraj U, Sofi S, Aisha S, Almilaibary A, Alkhanani M Medical Oncology, 1-3., 2022 | 31* | 2022 |
| Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis H Qayoom, S Sofi, MA Mir Immunologic Research 71 (4), 588-599, 2023 | 30 | 2023 |
| Rising trends of cancers in Kashmir valley: distribution pattern, incidence and causes H Qayoom, BA Bhat, U Mehraj, MA Mir J Oncol Res Treat 5 (150), 2, 2020 | 23 | 2020 |
| Cryptolepine targets TOP2A and inhibits tumor cell proliferation in breast cancer cells-an in vitro and in silico study U Mehraj, H Qayoom, S Shafi, P Farhana, S Asdaq, MA Mir Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2022 | 22 | 2022 |
| Mechanistic elucidation of Juglanthraquinone C targeting breast cancer: a network pharmacology-based investigation H Qayoom, M Alkhanani, A Almilaibary, SA Alsagaby, MA Mir Saudi Journal of Biological Sciences 30 (7), 103705, 2023 | 18 | 2023 |
| A comprehensive analysis of notch signaling genes in breast cancer: expression pattern and prognostic significance S Sofi, H Qayoom, N Jan, N Khaliq, A Almilaibary, MA Mir Advances in cancer biology-metastasis 7, 100104, 2023 | 14 | 2023 |
| Elucidation of interleukin-19 as a therapeutic target for breast cancer by computational analysis and experimental validation. S Sofi, N Jan, H Qayoom, M Alkhanani, A Almilaibary Saudi Journal of Biological Sciences 30 (9), 103774-103774, 2023 | 12 | 2023 |
| A network pharmacology-based investigation of brugine reveals its multi-target molecular mechanism against Breast Cancer H Qayoom, M Alkhanani, A Almilaibary, SA Alsagaby, MA Mir Medical Oncology 40 (7), 202, 2023 | 12 | 2023 |
| Conventional adjuvant chemotherapy in combination with surgery, radiotherapy, and other specific targets MA Mir, S Sofi, H Qayoom Combinational therapy in triple negative breast cancer. Elsevier, San Diego …, 2022 | 11 | 2022 |
| Integrating immunotherapy with chemotherapy: a new approach to drug repurposing H Qayoom, U Mehraj, S Aisha, S Sofi, MA Mir Drug repurposing molecular aspects and therapeutic applications, 2021 | 11 | 2021 |
| Proteomics: a groundbreaking development in cancer biology MA Mir, H Qayoom, S Sofi, N Jan Proteomics, 31-53, 2023 | 10 | 2023 |
| Introduction to breast cancer MA Mir, H Qayoom Therapeutic potential of cell cycle kinases in breast cancer, 1-22, 2023 | 9 | 2023 |
| Targeting biologically specific molecules in triple negative breast cancer (TNBC) chapter-7 M Mir, S Sofi, H Qayoom Combinational therapy in triple negative breast cancer. Elsevier Inc, San …, 2022 | 9 | 2022 |
| Proteomics: application of next-generation proteomics in cancer research MA Mir, H Qayoom, S Sofi, N Jan Proteomics, 55-76, 2023 | 8 | 2023 |
| Immuno-onco-metabolism and Therapeutic Resistance MA Mir, S Aisha, S Nisar, H Qayoom, U Mehraj Immuno-Oncology Crosstalk and Metabolism, 45-89, 2022 | 8 | 2022 |
Dr Manzoor Ahmad MirUniversity of KashmirVerified email at kashmiruniversity.ac.in
